3hon MSNOpinion
Why Tilray Stock Plunged Today
The legal status of marijuana in the U.S. remains scattered and confusing.
Wall Street is looking to the Fed policy meeting starting today for clues to the odds of more rate cuts in 2026.
Shares of Super Micro Computer have surged since the company's IPO, and the stock's forecast should catch investors' ...
This top TSX energy stock offers an attractive dividend yield and decent upside potential. The post 1 Magnificent Canadian ...
Here's what you need to know about whether U.S. stock markets will be open or closed on Christmas Eve and Christmas Day this year.
Zacks Investment Research on MSN
Coinbase stock slides 18.5% in 3 months: Time to buy the dip?
Shares of Coinbase Global Inc. COIN have lost 18.5% over the past three months compared with its industry’s decrease of 10.3% ...
Thursday, December 11, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including ...
Nvidia has denied reports that Chinese AI startup DeepSeek is using smuggled Blackwell GPUs, calling the claims "far-fetched.
Zacks Investment Research on MSN
Why this 1 medical stock could be a great addition to your portfolio
Here at Zacks, we offer our members many different opportunities to take full advantage of the stock market, as well as how to invest in ways that lead to long-term success. The Zacks Premium service ...
On Dec. 8, President Donald Trump posted on the social media platform Truth Social that he has "informed President Xi, of ...
Zacks Investment Research on MSN
Is UPS' cheap valuation reason enough to invest in the stock?
United Parcel Service UPS, the Atlanta-based parcel delivery heavyweight, looks highly attractive on valuation grounds. With a forward price-to-sales (P/S) of 0.97X, UPS stock trades at a discount to ...
Zacks Investment Research on MSN
NVO down 42% year to date: Is this an indication to sell the stock?
Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply constraints for its semaglutide-based GLP-1 blockbusters — Ozempic for type II ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results